Ketogenic Diet to Reduce Osteoarthritis Pain in MCI

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age55-75
SponsorUniversity of Kansas Medical Center

About this trial

Osteoarthritis and mild cognitive impairment are common conditions that share underlying biological processes related to metabolism and inflammation. This study will examine whether a well-formulated ketogenic diet influences pain, physical function, and cognitive outcomes in adults with osteoarthritis and mild cognitive impairment. Participants will follow a supervised ketogenic dietary intervention, with assessments conducted before and after the intervention to evaluate changes in symptoms and related biological markers. The goal of this study is to better understand shared mechanisms between joint pain and cognitive health and to explore whether a ketogenic dietary approach may support symptom management in these populations.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

English speaking

Diagnosis of major joint osteoarthritis

Diagnosis of mild cognitive impairment

Disqualifiers

Diabetes that requires insulin

Cancer requiring chemo- or radiation therapy in the last 2 years

Cardiac event within 1 year

Recent history of renal stones

Trial design

Design model

Single group

Treatments tested in this trial

  • Well-formulated ketogenic diet

    Other intervention

    This is a very low carbohydrate eating pattern that is higher in fat with adequate protein. This approach focuses on a nutrient dense, whole foods approach to a ketogenic diet and recommends 4-6 servings of non-starchy vegetables per day, 1/4 cup of berries per day, daily intake of nuts/seeds, fatty fish 2-3 times per week, and an emphasis on healthy fats like avocado, nuts, and olive oil.

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: Well-formulated ketogenic dietExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Pain intensity and pain interference using a Visual Analog Scale

Patient- and caregiver-reported outcome. 0-10 with higher scores reflecting worse pain.

Time frame
From enrollment to the end of treatment at 8 weeks
2

Health-related quality of life using a Questionnaire

Patient- and caregiver-reported ouctome.The PROMIS-29+2 Profile is a patient-reported outcome measure with domain scores converted to standardized T-scores (mean = 50, SD = 10), where higher scores indicate worse symptoms for anxiety, depression, fatigue, sleep disturbance, and pain interference, better functioning for physical function, social participation, and cognitive function, and pain intensity is rated separately on a 0-10 scale with higher scores indicating greater pain.

Time frame
From enrollment to end of treatment at 8 weeks
3

Physical Function via Functional Activities Questionnaire

Caregiver-reported outcome. FAQ is 0-30 with higher scores indicating worse impairment.

Time frame
From enrollment to end of treatment at 8 weeks.
4

Montreal Cognitive Assessment (MoCA) for brief global cognitive screening

Cognitive screener completed by the participant and administered by the study coordinator. The Montreal Cognitive Assessment (MoCA) is a 30-point cognitive screening tool assessing multiple cognitive domains, with total scores ranging from 0 to 30 and higher scores indicating better cognitive function.

Time frame
From enrollment to end of treatment at 8 weeks.

Secondary outcomes

1

Central sensitization

Physical assessment of the participant. Temporal summation is a quantitative sensory testing measure of central sensitization calculated as the increase in reported pain intensity following repeated identical stimuli, with higher values indicating greater pain facilitation.

Time frame
From enrollment to end of treatment at 8 weeks.
2

Ketone levels

We will run a correlational analysis on depth of ketosis and change in pain intensity. We will consider 'nutritional ketosis' as 0.5 mmol/L or higher.

Time frame
From enrollment to end of treatment at 8 weeks.

Other outcomes

1

Exploratory: Characterize ketogenic diet-induced changes in the gut

* Stool microbiome profiling * Alpha diversity (Observed species, Shannon, Chao1) * Beta diversity (Bray-Curtis, UniFrac) * Differential abundance of taxa associated with inflammation, SCFA production, bile acid metabolism, metabolic health, and neurodegeneration * Functional pathway analyses (PICRUSt2)

Time frame
From enrollment to end of treatment at 8 weeks.
2

Exploratory: Characterize ketogenic diet-induced changes in intraepidermal nerve fiber density

Skin biopsies -Intraepidermal nerve fiber density (IENFD)

Time frame
From enrollment to end of treatment at 8 weeks.
3

Exploratory: immunostaining skin sample for ASC, a marker of NLRP3 inflammasome activation

Marker expression will be reported as percent positive cells and/or immunoreactivity intensity quantified by digital image analysis (arbitrary units of optical density or fluorescence intensity) within defined regions of interest.

Time frame
From enrollment to end of the 8 weeks.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: